Sustained compensatory p38 MAPK signaling following treatment with MAPK inhibitors induces the immunosuppressive protein CD73 in cancer: combined targeting could improve outcomes

RAS‐MAPK signaling promotes immune evasion and cancer cell survival, and MAPK inhibitors (MAPKis) are frequently used as cancer therapies. Despite progress elucidating the direct effects of MAPKi on immune cells, their indirect effect on the tumor microenvironment (TME) through changes in tumor cell...

Descripción completa

Detalles Bibliográficos
Autores principales: Terp, Mikkel G., Gammelgaard, Odd L., Vever, Henriette, Gjerstorff, Morten F., Ditzel, Henrik J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8637576/
https://www.ncbi.nlm.nih.gov/pubmed/34165921
http://dx.doi.org/10.1002/1878-0261.13046

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8637576/
https://www.ncbi.nlm.nih.gov/pubmed/34165921
http://dx.doi.org/10.1002/1878-0261.13046

Ejemplares similares